Internal Reference Number: FOI_7473
Date Request Received: 09/10/2023 00:00:00
Date Request Replied To: 01/11/2023 00:00:00
This response was sent via: By Email
Request Summary: Lung cancer
Request Category: Researcher
| Question Number 1: How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: 鈥� ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) 鈥� Amivantamab 鈥� Atezolizumab Monotherapy 鈥� Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel 鈥� Dabrafenib + Trametinib 鈥� Docetaxel monotherapy or in combination with Carboplatin/Cisplatin 鈥� Durvalumab 鈥� Gemcitabine 鈥� Nitedanib + Docetaxel 鈥� Nivolumab 鈥� Osimertinib 鈥� Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) 鈥� Paclitaxel 鈥� Pembrolizumab Monotherapy 鈥� Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) 鈥� Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) 鈥� Pemetrexed + Platinum (Carboplatin/Cisplatin) 鈥� RET Inhibitors (Pralsetinib, Selpercatinib) 鈥� Sotorasib 鈥� Tepotinib 鈥� Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin 鈥� Other active systemic anti-cancer therapy 鈥� Palliative care only | |
| Answer To Question 1: Q. How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: 鈥� ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) <5 鈥� Amivantamab 0 鈥� Atezolizumab Monotherapy <5 鈥� Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel 0 鈥� Dabrafenib + Trametinib <5 鈥� Docetaxel monotherapy or in combination with Carboplatin/Cisplatin 0 鈥� Durvalumab <5 鈥� Gemcitabine 0 鈥� Nitedanib + Docetaxel 0 鈥� Nivolumab <5 鈥� Osimertinib <5 鈥� Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) 0 鈥� Paclitaxel 0 鈥� Pembrolizumab Monotherapy <5 鈥� Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) 0 鈥� Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) 5 鈥� Pemetrexed + Platinum (Carboplatin/Cisplatin) <5 鈥� RET Inhibitors (Pralsetinib, Selpercatinib) 0 鈥� Sotorasib <5 鈥� Tepotinib <5 鈥� Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin <5 鈥� Other active systemic anti-cancer therapy <5 (Cisplain/gemcitabine) 鈥� Palliative care only - Unable to answer, information not held | |
| Question Number 2: Does your trust/health board participate in any clinical trials for non-small cell lung cancer (NSCLC)? If so, could you please provide the name of each active trial and the number of patients taking part. | |
| Answer To Question 2: no | |
| To return to the list of all the FOI requests please click here |
Our staff at 69老湿机福利 District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
